Ubiosis

Ubiosis is a South Korean biotechnology company specializing in the development of microbiome-based therapeutics and diagnostic solutions. The company leverages its proprietary U-Biom platform to analyze the human microbiome and identify specific microbial strains with therapeutic potential for metabolic, inflammatory, and central nervous system disorders. Their pipeline includes candidates for non-alcoholic steatohepatitis (NASH), obesity, and autism spectrum disorder, focusing on the gut-brain and gut-liver axes. Ubiosis aims to provide personalized healthcare through microbiome monitoring and targeted live biotherapeutic products. The company also offers commercial microbiome testing services to consumers and researchers.